Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Share-based Compensation (2021 - 2025)

HCW Biologics (HCWB) has disclosed Share-based Compensation for 5 consecutive years, with $205492.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 11.59% year-over-year to $205492.0, compared with a TTM value of $1.1 million through Sep 2025, up 7.49%, and an annual FY2024 reading of $1.0 million, up 0.52% over the prior year.
  • Share-based Compensation was $205492.0 for Q3 2025 at HCW Biologics, down from $278307.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $349097.0 in Q4 2021 and bottomed at $1660.0 in Q3 2021.
  • Average Share-based Compensation over 5 years is $249597.0, with a median of $261272.0 recorded in 2023.
  • The sharpest move saw Share-based Compensation skyrocketed 18112.05% in 2022, then decreased 27.28% in 2023.
  • Year by year, Share-based Compensation stood at $349097.0 in 2021, then fell by 18.02% to $286188.0 in 2022, then decreased by 8.71% to $261272.0 in 2023, then rose by 11.79% to $292071.0 in 2024, then fell by 29.64% to $205492.0 in 2025.
  • Business Quant data shows Share-based Compensation for HCWB at $205492.0 in Q3 2025, $278307.0 in Q2 2025, and $275642.0 in Q1 2025.